Why Cartography Biosciences’ Phase 1 colorectal cancer trial matters after Samsung Ventures backing

Samsung wants oncology optionality beyond manufacturing. Cartography’s Phase 1 T-cell engager puts platform biology under pressure.

Samsung wants oncology optionality beyond manufacturing. Cartography’s Phase 1 T-cell engager puts platform biology under pressure.